Time zero (or T0) refers to the measurements before the treatment with olanzapine.

After that, the subsequent measurements were performed 1 month (time one or T1), 2 months (time two or T2), 9 months (time three or T3) and 12 months (time four or T4) after time zero respectively. Thus, each patient was his or her own control. All collections and assessments occurred during the hospitalization period and Inhibitors,research,lifescience,medical routine follow up post discharge of these patients. Anthropometric assessment Anthropometric evaluation consisted of determining the parameters height, weight (measured in the morning after fasting for 12 h), BMI calculated by dividing the body weight (kg) by the square of the height (m), arm circumference, WC, HC, WHR (dividing the value of WC by HC), bicep and tricep circumference, subscapular and suprailiac skinfold, resistance, body Inhibitors,research,lifescience,medical fat percentage and basal metabolic rate. Biochemical indicators and assay methods Blood samples were collected after 12 h of fasting for analysis of total cholesterol, high-density lipoprotein (HDL) Inhibitors,research,lifescience,medical and low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, insulin and cortisol. Statistical analysis The quantitative and qualitative variables were described as means, standard deviation and p value. Anthropometric and biochemical data were analyzed statistically using the Statistical Package for the Social Sciences (SPSS), version

16.0. The different parameters were tested individually by analysis of variance for repeated measures unifactorial, analyzing the factor time and the simple Inhibitors,research,lifescience,medical contrast of the initial measure with each of the subsequent analyses. The significance level was 5% (p < 0.05) for all analyses. Results Clinical and demographic

data showed no differences among the subjects, which suggests that they were homogeneous for age (χ2 = 3.59, p = 0.94) and sex (χ2 = 1.47, p = 0.26). The mean age of the subjects was 26.8 years, and the mean duration of the disorder was 67.8 weeks. Anthropometric measurements Inhibitors,research,lifescience,medical showed significant differences when comparing the mean values obtained in each of the different periods of data collection. The difference between the mean values for weight, BMI, WC and HC among the studied subjects showed significant increase (Table 1). The mean weight observed among our subjects increased from 66.9 kg ± 9.73 (mean ± SD) at T0 to 77.3 kg ± Dipeptidyl peptidase 13.4 (p = 0.002) 12 months after initiating treatment, when we performed our last evaluation. The prevalence of substantial weight gain (SWG) (subjects with weight gain greater than 7% of initial BMI) also showed prominent and progressive increase across each time point. Among our subjects, 30% showed SWG after 1 month of olanzapine use (T1 – T0). A drastic increase in this percentage was observed during the second evaluation (T2 – T0), when 63.3% of the participants presented SWG, which represents a twofold increase when Z-VAD-FMK nmr compared with the first measures (T1–T0).